10% Vaccine Plus Reverse Convertible Bond – available on secondary market

10% Vaccine Plus Reverse Convertible Bond – available on secondary market

2-year term, fixed annual interest rate of 10% and a barrier set at 60% of Johnson & Johnson, Moderna, Inc. and Pfizer Inc. – observation only at the end of the term!

The 10% Vaccine Plus Reverse Convertible Bond combines twofixed interest payments of 10% with a partial safety mechanism for the invested capital down to the barrier of 60% (only observed at maturity). The interest amount is paid out annually, regardless of the performance of the three underlying shares (Johnson & Johnson, Moderna, Inc. and Pfizer Inc.).

The share basket of the Reverse Convertible Bond consists of 3 US pharmaceutical companies, all of them successfully launching a vaccine against COVID-19 on the market::

  • After the Corona vaccine of the US pharmaceutical company Johnson & Johnson was released for the American market at the end of February, approval in Europe also followed in mid-March. The preparation is the first in the series of COVID vaccines, of which only one dose needs to be administered to achieve the full protective effect. 
  • The vaccine from the US pharmaceutical giant Pfizer Inc. is a so-called mRNA vaccine, which has been shown in studies to be particularly effective in preventing COVID -19 
    disease. In addition, the vaccine is mostly well tolerated and can therefore be used in all age groups. 
  • Moderna, Inc. is a US biotechnology company specializing in the research and development of mRNA-based drugs. The company‘s CoV vaccine is also based on this technology and, like Pfizer‘s, has been shown to provide a high level of protection against infections.

The certificate is redeemed at 100% of the nominal value at the maturity date (May 2023), provided that the daily closing price of each of the three underlying shares quote above the barrier of 60% of each respective strike on the final valuation date (observation only at maturity).

If one of the barriers is touched or undercut by the daily closing price of at least one of the underlying shares and at least one of these shares closes below its strike at the final valuation date, the predefined amount of the worst performing share is delivered (percentage performance from the starting value to the closing price at the final valuation date).

Further information as well as the Key Information Document please find on the Product Detail Page.

Reverse Convertible Bonds - explained in an easy way

Please adjust your cookie settings to allow YouTube videos or start the video here: External link to the video on YouTube

For any additional information you may require do not hesitate to contact us on +43 1 515 20-484.

The Team Structured Products of Raiffeisen Centrobank

Key facts:
  • Name: 10 % Impfstoff Plus Aktienanleihe
  • ISIN: AT0000A2QM90
  • Initial valuation date: May 11, 2021
  • Term: 1 year
    (Maturity date: May 12, 2023)
  • Listing: Vienna, Frankfurt, Stuttgart
Disclaimer
This is advertising. This non-binding information does not constitute advice, recommendation or invitation to conclude a transaction. The presentation is of a generic nature, does not take into account the personal circumstances of potential investors and therefore cannot replace individual investor and investment-oriented advice and risk disclosure. This advertisement has not been prepared in compliance with the legal provisions promoting the independence of investment research and is not subject to the ban on trading following the dissemination of investment research. A base prospectus (including any supplements) that complies with the Austrian Capital Market Act and has been approved by the competent authorities (CSSF, FMA) is available on the website of Raiffeisen Bank International AG (raiffeisencertificates.com/en/securities-prospectus/). The approval of the base prospectus by the competent authorities is not to be understood as an endorsement by the competent authorities of the financial instruments described herein. We recommend reading the prospectus before making an investment decision. Important additional information on the products described (in particular their opportunities and risks) can be found on the website of Raiffeisen Bank International AG at raiffeisencertificates.com/en/; in particular, the approved base prospectus (including any supplements) can be found at (raiffeisencertificates.com/en/securities-prospectus/) and under "Customer Information and Regulatory Issues" at raiffeisencertificates.com/en/customer-information/. Regulatory authorities: Austrian Financial Market Authority (FMA), European Central Bank (ECB). Imprint according to Austrian media law: Media owner and producer is Raiffeisen Bank International AG, Am Stadtpark 9, 1030 Vienna/Austria.